Trial · NCT07085728
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
NCT07085728, Phase 2, Recruiting, Eastern Cooperative Oncology Group
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure. Trials, record NCT07085728. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07085728
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
- NCT number
- NCT07085728
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 74 participants, estimated
- Lead sponsor
- Eastern Cooperative Oncology Group
- Conditions
- Myeloma Multiple
- Interventions
- Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone, Daratumumab-hyaluronidase
- First posted
- 2025-07-25
- Last updated
- 2026-09-14
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Renal Response Rate | Assessed every cycle on treatment up to 4 cycles (cycle duration=28 days) | Renal response rate (RRR) is the proportion of patients achieving complete or partial renal response based on International Myeloma Working Group (IMWG) renal response criteria (Dimopoulos 2023) over 4 cycles of treatment. |
| Secondary | Grade 3-5 Overall Toxicity Rate | Assessed every cycle on treatment up to 4 cycles (cycle duration=28 days) | Grade 3-5 overall toxicity rate is the proportion of participants who experience a maximum grade 3-5 treatment-related adverse event (AE) based on the Common Toxicity Criteria for Adverse Events Version 5.0 (CTCAEv5). |
| Secondary | Grade 3-5 Non-Hematologic Toxicity Rate | Assessed every cycle on treatment up to 4 cycles (cycle duration=28 days) | Grade 3-5 non-hematologic toxicity rate is the proportion of participants who experience a maximum grade 3-5 treatment-related non-hematologic AE based on CTCAEv5. |
| Secondary | Grade 3-5 Hematologic Toxicity Rate | Assessed every cycle on treatment up to 4 cycles (cycle duration=28 days) | Grade 3-5 hematologic toxicity rate is the proportion of participants who experience a maximum grade 3-5 treatment-related hematologic AE based on CTCAEv5. |
| Secondary | Best Response | Assessed every cycle on treatment up to 4 cycles (cycle duration=28 days) | Best response is the frequency of participants achieving stringent complete response (sCR), complete response (CR), partial response (PR), stable disease (SD) or disease progression (PD) based on International Myeloma Working Group (IMWG) uniform response criteria (URC; Durie 2006) over 4 cycles of treatment. |
| Secondary | Progression-Free Survival | Disease assessed every cycle on treatment (cycle duration=28 days) and in long-term follow-up every 3 months for years 1-2 and every 6 months years 3-10 | Progression-free survival (PFS) based on the Kaplan-Meier method defined as the time from randomization until the earlier of progression (PD per IMWG URC) or death due to any cause; Patients alive without disease progression will be censored at date of last disease evaluation; Only deaths that occur within 3 months of the last disease evaluation are considered events. |
| Secondary | Overall Survival | Assessed up to 10 years from study entry | Overall survival (OS) based on the Kaplan-Meier method is defined as the duration of time from treatment start to date of death or censored at the date last known alive. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07085728
GET https://conductscience.org/api/trials/v1/NCT07085728/registered